期刊文献+

冠脉介入治疗后再狭窄之中医药防治 被引量:5

Traditional Chinese Medicine in Treatment of Restenosis After Percutaneous Coronary Intervention
下载PDF
导出
摘要 经皮冠状动脉介入治疗是冠心病治疗的又一重要手段,然而介入后再狭窄问题始终困扰着医学界,成为当前医学界难题之一。张静生教授根据传统中医理论,结合多年临床经验,认为PCI术后再狭窄的形成主要涉及心、脾、肾三脏。病位在心,以气阴两虚为本,气滞、血瘀、痰浊为标。因此,治则以益气养阴为主,兼顾活血化瘀、祛痰、行气,并要注重防治结合,防在治先,顾护脾胃,调理情志。临床实践证实,此法在PCI术后再狭窄的治疗中取得了显著成效。 Percutaneous coronary intervention(PCI)is an important means of treating coronary heart disease,however,restenosis after PCI becomes one of the difficult problems.According to traditional Chinese medicine theory,combined with years of clinical experience,Professor ZHANG Jing-sheng suggested the formation of restenosis after PCI mainly involves the heart,spleen and kidney.This disease is principally due to deficiency of Qi and Yin,and secondarily due to Qi stagnation,blood stasis and phlegm.Therefore,the therapeutic method is invigorating Qi and nourishing Yin.Prevention and treatment should be combined together.Simultaneously,protecting stomach and spleen,and managing the emotional conditioning are also important.This method in the treatment of restenosis after PCI has achieved remarkable effects in clinical practice.
出处 《辽宁中医药大学学报》 CAS 2011年第6期142-143,共2页 Journal of Liaoning University of Traditional Chinese Medicine
关键词 PCI术后再狭窄 冠心病 中医药治疗 辨证论治 临床经验. PCI restenosis coronary heart disease traditional Chinese medicine diagnosis and treatment clinical experience
  • 相关文献

参考文献1

共引文献1

同被引文献63

  • 1万新焕,王瑜亮,周长征,郭浩,马山,王立柱.丹参化学成分及其药理作用研究进展[J].中草药,2020,51(3):788-798. 被引量:406
  • 2李立志.陈可冀治疗充血性心力衰竭经验[J].中西医结合心脑血管病杂志,2006,4(2):136-138. 被引量:184
  • 3王文燕,陈建光.五味子的药理作用及开发研究[J].北华大学学报(自然科学版),2007,8(2):128-133. 被引量:68
  • 4中华人民共和国卫生部.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002.115-119.
  • 5Bauters C, Isner JM. The biology of restenosis[J]. Progressin Cardiovascular Disease, 2007, 40: 107-116.
  • 6Gada H, Kirtane AJ, Newman W. 5-year results of a randomized comparison of XIENCE V everolimus-eluting and TAXUS Paclitaxel-eluting stents: final results from the SPIRIT III trial (clinical evaluation of the XIENCE V everolimus eluting coronary stent system in the treatment of patients with de novo native coronary artery lesions)[J].JACC Cardiovasc Interv, 2013,6(12):1263-1266.
  • 7Hao PP, Chen YG, Wang XI, et al. Efficacy and safety of drug-eluting stents in patients with acute ST-segment- elevation myocardial infarction: a meta-analysis of randomized controlled trials[J]. TexHcart Inst, 2010 37(5): 516-524.
  • 8Guerra E, Byrne RA, Kastrati A. Pharmacolo inhibition of coronary restenosis: systemic and glca loca approaches[J]. Expert Opin Pharmacother, 2014, 15(15) 2155-2171.
  • 9Schulz S, Sibbing D, Braun S, et al. Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents[J]. Am Heart, 2010, 160(2): 355-361.
  • 10Lei J, Vodovotz Y, Tzeng E, et al. Nitric oxide, a protective molecule in the cardiovascular system[J]. Nitric Oxide, 2013, 30(35): 175-185.

引证文献5

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部